In addition, we retrospectively analyzed a clinical cohort of 106 HR+/HER2− breast cancer patients receiving NAC and performed paired immunohistochemical (IHC) validation of CEACAM6 expression before and after treatment to examine its correlation with pCR status. The gene discussed is CEACAM6; the disease is breast carcinoma.